Klinik deneylerdeki Zavondemstat ilacı ve araştırma bileşiği QC6352, sanıldığı gibi KDM4 proteinini değil, esas olarak DHODH enzimini engelliyormuş.
October 7, 2026 at 1:14 PM
Klinik deneylerdeki Zavondemstat ilacı ve araştırma bileşiği QC6352, sanıldığı gibi KDM4 proteinini değil, esas olarak DHODH enzimini engelliyormuş.
Scientists hunting glioblastoma treatments accidentally found drug QC6352 is over 1000x more effective against protein DHODH than their original target, KDM4. That's a huge shift for brain cancer research!
October 8, 2026 at 6:04 PM
Scientists hunting glioblastoma treatments accidentally found drug QC6352 is over 1000x more effective against protein DHODH than their original target, KDM4. That's a huge shift for brain cancer research!
We thought QC6352 and zavondemstat worked as KDM4 inhibitors. Our new glioblastoma study shows their antitumour activity is actually driven by DHODH inhibition. I contributed to the preclinical therapeutic studies. #HGG #KDM4 www.nature.com/articles/s41...
DHODH is the key target of the KDM4 inhibitor QC6352 in glioblastoma stem cells - Nature Chemical Biology
QC6352, originally developed as a KDM4 inhibitor, exerts its anticancer activity in glioblastoma models primarily through inhibition of dihydroorotate dehydrogenase, a key enzyme in de novo pyrimidine...
www.nature.com
October 6, 2026 at 11:58 PM
We thought QC6352 and zavondemstat worked as KDM4 inhibitors. Our new glioblastoma study shows their antitumour activity is actually driven by DHODH inhibition. I contributed to the preclinical therapeutic studies. #HGG #KDM4 www.nature.com/articles/s41...
DHODH enziminin hedeflenmesi, agresif beyin kanseri türü olan glioblastom için yeni bir tedavi yolu sunabilir ve e ayrıca araştırmacılar KDM4'ü doğru incelemek amacıyla yeni bileşikler geliştirmişler.
October 7, 2026 at 1:17 PM
DHODH enziminin hedeflenmesi, agresif beyin kanseri türü olan glioblastom için yeni bir tedavi yolu sunabilir ve e ayrıca araştırmacılar KDM4'ü doğru incelemek amacıyla yeni bileşikler geliştirmişler.
QC6352, once considered “best-in-class,” has a hidden liability. New research shows it is a dual KDM4–DHODH inhibitor, with DHODH driving activity in glioblastoma models. We’re updating the Chemical Probes Portal with a warning and guidance on controls. #DrugDiscovery
www.nature.com/articles/s41...
www.nature.com/articles/s41...
DHODH is the key target of the KDM4 inhibitor QC6352 in glioblastoma stem cells - Nature Chemical Biology
QC6352, originally developed as a KDM4 inhibitor, exerts its anticancer activity in glioblastoma models primarily through inhibition of dihydroorotate dehydrogenase, a key enzyme in de novo pyrimidine...
www.nature.com
October 6, 2026 at 10:40 AM
QC6352, once considered “best-in-class,” has a hidden liability. New research shows it is a dual KDM4–DHODH inhibitor, with DHODH driving activity in glioblastoma models. We’re updating the Chemical Probes Portal with a warning and guidance on controls. #DrugDiscovery
www.nature.com/articles/s41...
www.nature.com/articles/s41...
QC6352, originally developed as a KDM4 inhibitor, exerts its anticancer activity in glioblastoma models primarily through inhibition of DHODH, a key enzyme in de novo pyrimidine biosynthesis
www.nature.com/articles/s41...
www.nature.com/articles/s41...
DHODH is the key target of the KDM4 inhibitor QC6352 in glioblastoma stem cells - Nature Chemical Biology
QC6352, originally developed as a KDM4 inhibitor, exerts its anticancer activity in glioblastoma models primarily through inhibition of dihydroorotate dehydrogenase, a key enzyme in de novo pyrimidine...
www.nature.com
October 7, 2026 at 6:07 PM
QC6352, originally developed as a KDM4 inhibitor, exerts its anticancer activity in glioblastoma models primarily through inhibition of DHODH, a key enzyme in de novo pyrimidine biosynthesis
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Its been a great week for our lab! 🎉 I am excited to share our lab’s second publication!
www.science.org/eprint/W9M5J...
www.science.org/eprint/W9M5J...
Epigenetic reactivation of the tumor suppressor ZBTB7A by KDM4 inhibition in human acute myeloid leukemia
CRISPR screens identify ZBTB7A as a tumor suppressor gene, and therapeutic targeting of KDM4 restores its expression to promote AML differentiation.
www.science.org
February 25, 2026 at 7:17 PM
Its been a great week for our lab! 🎉 I am excited to share our lab’s second publication!
www.science.org/eprint/W9M5J...
www.science.org/eprint/W9M5J...
アボカド🥑の高糖度種KDM4-4の生育が好調です。再来年には開花するかも。それを目指して鉢増しする動画です。
youtu.be/pz5tjL2sfV8?...
youtu.be/pz5tjL2sfV8?...
アボカド🥑甘味種KDM4-4の植え替え replant Avocado 🥑 Sweetness variety ‘KDM4-4’
YouTube video by Vicky Polon
youtu.be
September 13, 2024 at 8:37 AM
アボカド🥑の高糖度種KDM4-4の生育が好調です。再来年には開花するかも。それを目指して鉢増しする動画です。
youtu.be/pz5tjL2sfV8?...
youtu.be/pz5tjL2sfV8?...
Epigenetics Update - Epigenetic reactivation of the tumor suppressor ZBTB7A by KDM4 inhibition in human acute myeloid leukemia bit.ly/3MPjl8s
Eric Wang (Uni. Connecticut) reporting in Science TM
#Epigenetics #KDM4 #Cancer #AML
---
Empower your research at epigenometech.com
Eric Wang (Uni. Connecticut) reporting in Science TM
#Epigenetics #KDM4 #Cancer #AML
---
Empower your research at epigenometech.com
Epigenetic reactivation of the tumor suppressor ZBTB7A by KDM4 inhibition in human acute myeloid leukemia
CRISPR screens identify ZBTB7A as a tumor suppressor gene, and therapeutic targeting of KDM4 restores its expression to promote AML differentiation.
bit.ly
February 27, 2026 at 1:02 PM
Epigenetics Update - Epigenetic reactivation of the tumor suppressor ZBTB7A by KDM4 inhibition in human acute myeloid leukemia bit.ly/3MPjl8s
Eric Wang (Uni. Connecticut) reporting in Science TM
#Epigenetics #KDM4 #Cancer #AML
---
Empower your research at epigenometech.com
Eric Wang (Uni. Connecticut) reporting in Science TM
#Epigenetics #KDM4 #Cancer #AML
---
Empower your research at epigenometech.com
Cancer trial drug zavondemstat largely blocks DHODH rather than its intended KDM4 targets. The mismatch may have implications for its ongoing clinical development.
Cancer trial drug may work differently than scientists believed, raising concerns for clinical research
A cancer drug currently being tested in patients may have entered clinical trials based on an incorrect understanding of how it works, according to a new study led by the University of Sydney in collaboration with Goethe University, Oxford University and the Institute of Cancer Research, London.
medicalxpress.com
October 6, 2026 at 9:00 AM
Cancer trial drug zavondemstat largely blocks DHODH rather than its intended KDM4 targets. The mismatch may have implications for its ongoing clinical development.
The authors included RRIDs in their None paper! RRIDs improve reproducibility in scientific research. #accelerateopenscience #methodsmatter #accelerateopenscience
Genome-wide Kdm4 histone demethylase transcriptional regulation in Drosophila
doi.org
July 30, 2025 at 7:00 AM
The authors included RRIDs in their None paper! RRIDs improve reproducibility in scientific research. #accelerateopenscience #methodsmatter #accelerateopenscience
The authors included RRIDs in their None paper! We value the author's support of reproducibility. #methodsmatter #accelerateopenscience #reproducibility
Epigenetic editing and epi-drugs: a combination strategy to simultaneously target KDM4 as a novel anticancer approach
doi.org
July 23, 2025 at 7:02 AM
The authors included RRIDs in their None paper! We value the author's support of reproducibility. #methodsmatter #accelerateopenscience #reproducibility
🎓 Viernes 07 a las 10:30h
Defensa de tesis doctoral de nuestra compañera Cintia Fonseca, bajo la dirección de la Dra. Veronique Smits
«Regulations of KDM4 histone demethylases: implications for genome integrity»
¡Mucho éxito! 💪
#Investigación #TesisDoctoral #ITB
Defensa de tesis doctoral de nuestra compañera Cintia Fonseca, bajo la dirección de la Dra. Veronique Smits
«Regulations of KDM4 histone demethylases: implications for genome integrity»
¡Mucho éxito! 💪
#Investigación #TesisDoctoral #ITB
November 3, 2025 at 3:49 PM
🎓 Viernes 07 a las 10:30h
Defensa de tesis doctoral de nuestra compañera Cintia Fonseca, bajo la dirección de la Dra. Veronique Smits
«Regulations of KDM4 histone demethylases: implications for genome integrity»
¡Mucho éxito! 💪
#Investigación #TesisDoctoral #ITB
Defensa de tesis doctoral de nuestra compañera Cintia Fonseca, bajo la dirección de la Dra. Veronique Smits
«Regulations of KDM4 histone demethylases: implications for genome integrity»
¡Mucho éxito! 💪
#Investigación #TesisDoctoral #ITB
🧬🧪 EpiCypher is excited to share our work with @dkjhaunc.bsky.social & the Daley lab on novel epigenetic targets for diffuse large B-cell lymphoma (DLBCL) therapy.
Specifically, this research showed that DLBCL is highly sensitive to KDM4 inhibitors. (1/n)
www.biorxiv.org/content/10.1...
Specifically, this research showed that DLBCL is highly sensitive to KDM4 inhibitors. (1/n)
www.biorxiv.org/content/10.1...
February 10, 2025 at 2:43 PM
🧬🧪 EpiCypher is excited to share our work with @dkjhaunc.bsky.social & the Daley lab on novel epigenetic targets for diffuse large B-cell lymphoma (DLBCL) therapy.
Specifically, this research showed that DLBCL is highly sensitive to KDM4 inhibitors. (1/n)
www.biorxiv.org/content/10.1...
Specifically, this research showed that DLBCL is highly sensitive to KDM4 inhibitors. (1/n)
www.biorxiv.org/content/10.1...
🐘 The final midweek home game of the #KDMEvolutionTrophy league phase.
🆚 Kilmarnock B
📍The Rock - sponsored by Marbill Coaches
🕒 7.45pm
🏆 KDM Trophy
🎟️ https://app.fanbaseclub.com/fixture/dumbarton/21836
📰 https://dumbartonfootballclub.com/fixtures/dumbarton-v-kilmarnock-b-220926-kdm4/
🆚 Kilmarnock B
📍The Rock - sponsored by Marbill Coaches
🕒 7.45pm
🏆 KDM Trophy
🎟️ https://app.fanbaseclub.com/fixture/dumbarton/21836
📰 https://dumbartonfootballclub.com/fixtures/dumbarton-v-kilmarnock-b-220926-kdm4/
September 22, 2026 at 11:14 AM
🐘 The final midweek home game of the #KDMEvolutionTrophy league phase.
🆚 Kilmarnock B
📍The Rock - sponsored by Marbill Coaches
🕒 7.45pm
🏆 KDM Trophy
🎟️ https://app.fanbaseclub.com/fixture/dumbarton/21836
📰 https://dumbartonfootballclub.com/fixtures/dumbarton-v-kilmarnock-b-220926-kdm4/
🆚 Kilmarnock B
📍The Rock - sponsored by Marbill Coaches
🕒 7.45pm
🏆 KDM Trophy
🎟️ https://app.fanbaseclub.com/fixture/dumbarton/21836
📰 https://dumbartonfootballclub.com/fixtures/dumbarton-v-kilmarnock-b-220926-kdm4/
Kicking off a #KDMEvolutionTrophy double header at home.
We welcome @kilmarnockfc.co.uk B to The Rock - sponsored by Marbill Coaches tomorrow night on matchday four of the competition.
Everything you need to know ⬇️
https://dumbartonfootballclub.com/fixtures/dumbarton-v-kilmarnock-b-220926-kdm4/
We welcome @kilmarnockfc.co.uk B to The Rock - sponsored by Marbill Coaches tomorrow night on matchday four of the competition.
Everything you need to know ⬇️
https://dumbartonfootballclub.com/fixtures/dumbarton-v-kilmarnock-b-220926-kdm4/
September 21, 2026 at 3:30 PM
Kicking off a #KDMEvolutionTrophy double header at home.
We welcome @kilmarnockfc.co.uk B to The Rock - sponsored by Marbill Coaches tomorrow night on matchday four of the competition.
Everything you need to know ⬇️
https://dumbartonfootballclub.com/fixtures/dumbarton-v-kilmarnock-b-220926-kdm4/
We welcome @kilmarnockfc.co.uk B to The Rock - sponsored by Marbill Coaches tomorrow night on matchday four of the competition.
Everything you need to know ⬇️
https://dumbartonfootballclub.com/fixtures/dumbarton-v-kilmarnock-b-220926-kdm4/
Metabolic-Epigenetic Coupling in Cellular Senescence: In Silico Cristae Remodeling Depletes Alpha-Ketoglutarate to Drive KDM4/6 Inhibition and SASP Amplification https://www.biorxiv.org/content/10.64898/2026.09.16.752165v1
September 18, 2026 at 11:00 AM
Metabolic-Epigenetic Coupling in Cellular Senescence: In Silico Cristae Remodeling Depletes Alpha-Ketoglutarate to Drive KDM4/6 Inhibition and SASP Amplification https://www.biorxiv.org/content/10.64898/2026.09.16.752165v1
Metabolic-Epigenetic Coupling in Cellular Senescence: In Silico Cristae Remodeling Depletes Alpha-Ketoglutarate to Drive KDM4/6 Inhibition and SASP Amplification https://www.biorxiv.org/content/10.64898/2026.09.16.752165v1
September 18, 2026 at 11:00 AM
Metabolic-Epigenetic Coupling in Cellular Senescence: In Silico Cristae Remodeling Depletes Alpha-Ketoglutarate to Drive KDM4/6 Inhibition and SASP Amplification https://www.biorxiv.org/content/10.64898/2026.09.16.752165v1
Bonus!
This work leveraged EpiCypher's dCypher™ platform to characterize novel KDM4 inhibitors.
Unlike other histone-peptide based platforms, dCypher assays use nucleosomes.
Why is this important? (3/n)
This work leveraged EpiCypher's dCypher™ platform to characterize novel KDM4 inhibitors.
Unlike other histone-peptide based platforms, dCypher assays use nucleosomes.
Why is this important? (3/n)
February 10, 2025 at 2:43 PM
Bonus!
This work leveraged EpiCypher's dCypher™ platform to characterize novel KDM4 inhibitors.
Unlike other histone-peptide based platforms, dCypher assays use nucleosomes.
Why is this important? (3/n)
This work leveraged EpiCypher's dCypher™ platform to characterize novel KDM4 inhibitors.
Unlike other histone-peptide based platforms, dCypher assays use nucleosomes.
Why is this important? (3/n)
KDM4 Orchestrates Epigenomic Remodeling of Senescent Cells and Potentiates the Senescence-Associated Secretory Phenotype
onlinelibrary.wiley.com/doi/full/10....
onlinelibrary.wiley.com/doi/full/10....
KDM4 Orchestrates Epigenomic Remodeling of Senescent Cells and Potentiates the Senescence‐Associated Secretory Phenotype
The chromatin accessibility landscape of senescent cells is remodeled, with a set of activated transcription factors physically binding to the enhancers and promoters of senescence-associated genes, ...
onlinelibrary.wiley.com
August 25, 2025 at 1:07 PM
KDM4 Orchestrates Epigenomic Remodeling of Senescent Cells and Potentiates the Senescence-Associated Secretory Phenotype
onlinelibrary.wiley.com/doi/full/10....
onlinelibrary.wiley.com/doi/full/10....
Additionally, some JmjC-KDMs can also lead to hydroxylation of the C4 position of arginines, which makes them extremely versatile, but also hard to study enzymes. (4/5) www.nature.com/articles/s42...
JmjC catalysed histone H2a N-methyl arginine demethylation and C4-arginine hydroxylation reveals importance of sequence-reactivity relationships - Communications Biology
The JmjC histone demethylases KDM4 and KDM5 catalyse demethylation of N-methylated Arg-3 of histone H2a, and KDM4E is found − unexpectedly − to catalyse C-4 hydroxylation of Arg-20 of H2a.
www.nature.com
January 31, 2025 at 9:41 AM
Additionally, some JmjC-KDMs can also lead to hydroxylation of the C4 position of arginines, which makes them extremely versatile, but also hard to study enzymes. (4/5) www.nature.com/articles/s42...
Heterochromatin fidelity is a therapeutic vulnerability in lymphoma and other human cancers [new]
KDM4A/C inhibition disrupts heterochromatin, causing lymphoma cytotoxicity/DNA damage. KDM4 dysregulation occurs in cancers.
KDM4A/C inhibition disrupts heterochromatin, causing lymphoma cytotoxicity/DNA damage. KDM4 dysregulation occurs in cancers.
February 6, 2025 at 4:00 PM
Heterochromatin fidelity is a therapeutic vulnerability in lymphoma and other human cancers [new]
KDM4A/C inhibition disrupts heterochromatin, causing lymphoma cytotoxicity/DNA damage. KDM4 dysregulation occurs in cancers.
KDM4A/C inhibition disrupts heterochromatin, causing lymphoma cytotoxicity/DNA damage. KDM4 dysregulation occurs in cancers.
Solución a problema de script RC para KDM4, de #KDE SC 4.6.1 en #FreeBSD en versión 8.1 del sistema: https://mail.kde.org/pipermail/kde-freebsd/2011-March/010553.html
November 19, 2024 at 9:46 AM
Solución a problema de script RC para KDM4, de #KDE SC 4.6.1 en #FreeBSD en versión 8.1 del sistema: https://mail.kde.org/pipermail/kde-freebsd/2011-March/010553.html